Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Victorian Clinical Genetics Services, |
RCV002272804 | SCV002557184 | pathogenic | Telangiectasia, hereditary hemorrhagic, type 2 | 2022-02-02 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with telangiectasia, hereditary hemorrhagic, type 2 (MIM#600376). PTC variants are known to cause disease through a loss of function mechanism, while missense variants are known to cause disease through either loss of function or dominant negative mechanisms (PMID: 26176610, PMID: 16470589, PMID: 16282348). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Clinical expression is known to be extremely variable and age-dependent (PMID: 19767588). (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. Other variants predicted to cause NMD have previously been reported in individuals with hereditary hemorrhagic telangiectasia (ClinVar, DECIPHER, PMID: 15993872, PMID: 16470589). (SP) 0807 - This variant has no previous evidence of pathogenicity. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |